Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jun;3(3):306-315.
doi: 10.1016/j.euo.2020.02.007. Epub 2020 Mar 19.

Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Affiliations
Meta-Analysis

Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Sungmin Woo et al. Eur Urol Oncol. 2020 Jun.

Erratum in

Abstract

Context: A noninvasive multiparametric magnetic resonance imaging (MRI)-based scoring system for predicting muscle-invasive bladder cancer (MIBC), the "Vesical Imaging Reporting and Data System" (VI-RADS), was recently developed by an international multidisciplinary panel. Since then, a few studies evaluating the value of VI-RADS for predicting MIBC have been published.

Objective: To review the diagnostic performance of VI-RADS for the prediction of MIBC.

Evidence acquisition: PubMed and EMBASE databases were searched up to November 10, 2019. We included diagnostic accuracy studies using VI-RADS to predict MIBC using cystectomy or transurethral resection as the reference standard. Methodological quality was evaluated with Quality Assessment of Diagnostic Accuracy Studies-2. Sensitivity and specificity were pooled and plotted using hierarchical summary receiver operating characteristics (HSROC) modeling. Meta-regression analyses were done to explore heterogeneity.

Evidence synthesis: Six studies (1770 patients) were included. Pooled sensitivity and specificity were 0.83 (95% confidence interval [CI] 0.70-0.90) and 0.90 (95% CI 0.83-0.95), and the area under the HSROC curve was 0.94 (95% CI 0.91-0.95). Heterogeneity was present among the studies (Q = 29.442, p < 0.01; I2 = 87.93%, and 90.99% for sensitivity and specificity). Meta-regression analyses showed that the number of patients (>205 vs ≤205), magnetic field strength (3 vs 1.5 T), T2-weighted image slice thickness (3 vs 4 mm), and VI-RADS cutoff score (≥3 vs ≥4) were significant factors affecting heterogeneity (p ≤ 0.03).

Conclusions: VI-RADS shows good sensitivity and specificity for determining MIBC. Technical factors associated with MRI acquisition and cutoff scores need to be taken into consideration as they may affect performance.

Patient summary: A recently established noninvasive magnetic resonance imaging-based scoring system shows good diagnostic performance in detecting muscle-invasive bladder cancer.

Keywords: Bladder cancer; Magnetic resonance imaging; Meta-analysis; Muscle invasive; Systematic review; Vesical Imaging Reporting and Data System.

PubMed Disclaimer

Figures

Fig. 1 –
Fig. 1 –
Study selection process.
Fig. 2 –
Fig. 2 –
Grouped bar charts show (A) risk of bias and (B) concerns for applicability of six studies included in meta-analysis using QUADAS-2. QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies-2.
Fig. 3 –
Fig. 3 –
Hierarchical summary receiver operating characteristic curve showing diagnostic performance of studies using VI-RADS for the prediction of muscle-invasive bladder cancer. HSROC = hierarchical summary receiver operating characteristics; VI-RADS = Vesical Imaging Reporting and Data System.
Fig. 4 –
Fig. 4 –
Coupled forest plots of sensitivity and specificity. Numbers are pooled estimates with 95% confidence intervals (CIs) in parentheses and heterogeneity statistics are shown at bottom right. Horizontal lines indicate 95% CIs. df = degree of freedom.
Fig. 5
Fig. 5
– Deeks’ funnel plot. A p value of 0.52 indicates absence of publication bias. ESS = effective sample size.

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Josephson D, Pasin E, Stein JP. Superficial bladder cancer: part 2. Management. Expert Rev Anticancer Ther 2007;7:567–81. - PubMed
    1. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196:1021–9. - PubMed
    1. Babjuk M, Burger M, Comperat EM, et al. European Association of Urology guidelines on non-muscle- invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 2019;76:639–57. - PubMed
    1. Naselli A, Hurle R, Paparella S, et al. Role of restaging transurethral resection for T1 non–muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 2018;4:558–67. - PubMed

Publication types

MeSH terms